Last $0.06 USD
Change Today -0.0001 / -0.17%
Volume 56.2K
VNTH On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

vantage health (VNTH) Snapshot

Open
$0.06
Previous Close
$0.06
Day High
$0.06
Day Low
$0.06
52 Week High
06/20/14 - $0.35
52 Week Low
12/12/14 - $0.02
Market Cap
11.7M
Average Volume 10 Days
393.0K
EPS TTM
--
Shares Outstanding
196.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VANTAGE HEALTH (VNTH)

Related News

No related news articles were found.

vantage health (VNTH) Related Businessweek News

No Related Businessweek News Found

vantage health (VNTH) Details

Vantage Health Inc. operates as a mobile healthcare technology company in the United States. It is involved in developing personalized and point-of-care screening using applications based upon chemical sensing residing in a small device attached to a smartphone. The company provides the Vantage Health Sensor, a convergence of nano-electronics, bio-informatics, and wireless technology that create mobile health applications. It has a strategic partnership with Scripps Translational Sciences Institute to assist in the development, advancement, and commercialization of the mobile technology. The company was incorporated in 2010 and is based in Redwood City, California. Vantage Health Inc. operates as a subsidiary of Nanobeak, Inc.

12 Employees
Last Reported Date: 10/15/14
Founded in 2010

vantage health (VNTH) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

vantage health (VNTH) Key Developments

Vantage Health Inc. Provides Update on Scientific Developments

Vantage Health Inc. announced scientific updates. Over the last three months Vantage, and its parent company, has been developing version 2.0 of its sensor technology. Version 2.0 operates on a Bluetooth platform eliminating the need for physical connections to multiple smartphone platforms. The new sensor is wirelessly compatible with all devices that have Bluetooth capability and will also operate with tablet technology. Version 2.0 of the sensor has the capacity to be scaled up to 256 sensor channels. The molecular samples analyzed by the Vantage Sensor 2.0 were sent to a third party laboratory specializing in analytical, environmental and pharmacological testing. When testing for lower and higher concentrations of certain molecules, which are important biomarkers in disease detection, results suggested that the sensor may actually be more sensitive than Gas Chromatography--Mass Spectrometry (GC-MS). A GC-MS is considered the gold standard for molecular analysis typically costing as much as six figures. Vantage plans to retail this sensor for less than $200. A provisional patent was filed recently to protect the proprietary algorithm used to convert the nano-sensor data into useful calibrated measurements. The key inventor, formerly a NASA contractor, has been engaged to help imbed the algorithm into hand-held apps that communicate directly with the new Bluetooth device. The Company also recruited two additional staff members; a Chief Scientist for Nanotechnology who brings 10 years of experience and a Chief Technology Officer who brings 16 years of experience. The company and its partners have just completed version 3.0 of a breath capture device, which attaches directly onto the sensor. The breath capture device allows for unlimited use of the sensor without the risk of contamination between patients and also includes a filtering mechanism, removing water vapor in the breath, which could otherwise interfere with the molecular analysis. The parent company will be filing another provisional patent for this technology as well.

Vantage Health Inc. Auditor Raises 'Going Concern' Doubt

Vantage Health Inc. filed its 10-K on Oct 14, 2014 for the period ending Jun 30, 2014. In this report its auditor, Malone & Bailey, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Vantage Health Inc. Appoints Tony Van Bijleveld as an Independent Member of Board of Directors

Vantage Health has appointed Tony van Bijleveld as an independent member of the Board of Directors of company. Van Bijleveld is currently General Manager with drug manufacturer Patheon/DPX. Over the past 30 years he has served in a variety of senior executive capacities in the pharmaceutical and biotech industry including: Managing Director of United Drug PLC, President/General Manager Russia for Schering Plough/MSD, SVP of Organon Biosciences, and Managing Director of KCL Foundation Labs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNTH:US $0.06 USD -0.0001

VNTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNTH.
View Industry Companies
 

Industry Analysis

VNTH

Industry Average

Valuation VNTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANTAGE HEALTH, please visit www.vantagehealthinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.